These Analysts Revise Their Forecasts On Caris Life Sciences Following Q4 Earnings

Core Insights - Caris Life Sciences Inc. reported better-than-expected fourth-quarter earnings, with earnings of 28 cents compared to a consensus loss of 3 cents, and sales increased by 125% year over year to $292.89 million, surpassing the consensus of $208.63 million [1] Group 1: Financial Performance - The company achieved fourth-quarter earnings of 28 cents, significantly exceeding the expected loss of 3 cents [1] - Sales for the quarter rose 125% year over year to $292.89 million, beating the consensus estimate of $208.63 million [1] Group 2: Future Growth Prospects - The demand for Caris Life Sciences' platform is accelerating, contributing to strong growth in volume and revenue, with plans to launch the Caris Detect solution in the first half of 2026, which is seen as a significant growth opportunity [2] - The company reported advancements in its multi-cancer early detection test, Caris Detect, which utilizes Whole Genome Sequencing to improve early cancer detection capabilities [3] Group 3: Market Reaction and Analyst Ratings - Following the earnings announcement, Caris Life Sciences shares increased by 14.1% to $21.95 in pre-market trading [3] - Analysts have adjusted their price targets for Caris Life Sciences, with BTIG maintaining a Buy rating and lowering the target from $45 to $38, Baird maintaining an Outperform rating and raising the target from $26 to $28, and Evercore ISI Group maintaining an Outperform rating and lowering the target from $38 to $34 [4]